Mereo Biopharma Group Plc ADR Dossier
|
SectorHealth Care IndustryBiotechnology Beta (adjusted)0.54 Intrinsic Value No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference. Market Price $0.37Price as of 1 Oct 2026 Data confidence Sign in to view data confidence Market Cap $58.6M Enterprise Value $28.5M Shares Outstanding 159.7M diluted Next Earnings Date9 Nov 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary Mereo BioPharma is a clinical-stage biopharmaceutical company focused on rare diseases. Despite missing primary fracture reduction endpoints in its Phase 3 Orbit and Cosmic trials for setrusumab, the drug demonstrated highly significant improvements in bone mineral density and vertebral fracture reductions. The company is actively engaging regulators to establish a pediatric approval pathway. Additionally, Mereo is pursuing a strategic partnership to advance alvelestat into Phase 3 for AATD-LD, which could serve as a major non-dilutive funding catalyst. Backed by a cash runway extending into mid-2027 and a lean operating model, Mereo presents an asymmetric risk-reward profile for biotech investors. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$1.00 Mean target$2.00 High · most bullish analyst$3.01 Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario Regulatory agencies reject the pediatric pathway for setrusumab, requiring new clinical trials. Partnering discussions for alvelestat stall, forcing Mereo to either delay Phase 3 development or raise highly dilutive equity capital as its cash runway approaches mid-2027. Base CaseCentral scenario Regulators agree to a pediatric approval pathway for setrusumab based on robust secondary bone mineral density data. Concurrently, Mereo secures a development partner for alvelestat, triggering upfront payments and initiating Phase 3 trials. The cash runway is successfully extended beyond 2027 without significant equity dilution. Bull CaseUpside scenario The bull case relies on a successful regulatory path forward for setrusumab in pediatric osteogenesis imperfecta (OI) patients despite missing primary fracture-rate endpoints, alongside securing a high-value strategic partnership to fund and execute the Phase 3 trial of alvelestat in AATD-LD. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
Thesis Invalidation Triggers
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |